Amerikanische Gesellschaft für Hirudotherapie

Treatment of heparin-induced thrombocytopenia

Review published in Ann Pharmacother (2002)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewArzneimittelentwicklungKlinische StudienDager WE et al. · Ann Pharmacother, 2002

Abstract

OBJECTIVE: To describe heparin-induced thrombocytopenia (HIT or HIT-2), an immune-mediated adverse reaction to heparin or low-molecular-weight heparin. Available treatment options and considerations in developing a therapy approach are discussed. DATA SOURCES: A search of the National Library of Medicine (1992-June 2001) was done to identify pertinent literature. Additional references were reviewed from selected articles. STUDY SELECTION: Articles related to laboratory recognition and treatment options of HIT, including the use of agents in selected clinical conditions, were reviewed and included. CONCLUSIONS: HIT is a rare but potentially severe adverse reaction to heparin that was, until recently, poorly understood and had limited treatment options. Recent advances describing the recognition and clinical manifestations of immune-mediated HIT, including recently available antithrombotic treatment options, have dramatically changed outcomes for patients having this syndrome.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnimalsAnticoagulantsArginineChondroitin SulfatesClinical Trials as TopicCoronary DiseaseDermatan SulfateDrug CombinationsFemaleHeparinHeparan SulfateHirudin Therapy

Zusammenfassung

Review of HIT-2 treatment options including direct thrombin inhibitors such as lepirudin and argatroban; describes laboratory recognition and clinical manifestations of immune-mediated HIT.

Warum dies für die Hirudotherapie relevant ist

This article describes heparin-induced thrombocytopenia (HIT or HIT-2) as an immune-mediated adverse reaction to heparin or low-molecular-weight heparin and discusses available antithrombotic treatment options based on a literature search through June 2001. The abstract notes that recent advances in recognition and treatment options have improved outcomes for these patients. The abstract does not name any specific antithrombotic agent and makes no mention of hirudin, leeches, or hirudotherapy. There is no defensible connection to ASH's domain based on this abstract alone; any hirudin-related link would require external knowledge not present in the text.

Zitation

Treatment of heparin-induced thrombocytopenia.

Dager WE et al. · Ann Pharmacother, 2002

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.